{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T19:58:12Z","timestamp":1789243092108,"version":"build-2803163510"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2021,8,3]],"date-time":"2021-08-03T00:00:00Z","timestamp":1627948800000},"content-version":"vor","delay-in-days":2,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1007\/s40265-021-01562-6","type":"journal-article","created":{"date-parts":[[2021,8,3]],"date-time":"2021-08-03T15:43:50Z","timestamp":1628005430000},"page":"1411-1422","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":41,"title":["Budesonide\/Glycopyrronium\/Formoterol: A Review in COPD"],"prefix":"10.1007","volume":"81","author":[{"given":"Young-A","family":"Heo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,8,3]]},"reference":[{"key":"1562_CR1","unstructured":"Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. 2021. http:\/\/www.goldcopd.org\/. Accessed 24 May 2021."},{"key":"1562_CR2","doi-asserted-by":"publisher","first-page":"417","DOI":"10.2147\/COPD.S234823","volume":"15","author":"S Zhang","year":"2020","unstructured":"Zhang S, King D, Rosen VM, et al. Impact of single combination inhaler versus multiple inhalers to deliver the same medications for patients with asthma or COPD: a systematic literature review. Int J Chron Obstruct Pulmon Dis. 2020;15:417\u201338.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"1562_CR3","unstructured":"AstraZeneca. BREZTRI AEROSPHERE\u2122 (budesonide, glycopyrrolate, and formoterol fumarate) inhalation aerosol, for oral inhalation use. 2020. http:\/\/www.fda.gov\/. Accessed 24 May 2021."},{"key":"1562_CR4","unstructured":"European Medicines Agency. Summary of product characteristics: TRIXEO AEROSPHERE\u2122 5 micrograms\/7.2 micrograms\/160 micrograms pressurised inhalation, suspension. 2021. https:\/\/www.ema.europa.eu\/. Accessed 24 May 2021."},{"key":"1562_CR5","unstructured":"AstraZeneca. AstraZeneca\u2019s triple-combination therapy approved in China for patients with COPD [media release]. 2019. https:\/\/www.astrazeneca.com\/. Accessed 24 May 2021."},{"key":"1562_CR6","unstructured":"AstraZeneca. BREZTRI AEROSPHERE (PT010) approved in Japan for patients with chronic obstructive pulmonary disease [media release]. 2019. https:\/\/www.astrazeneca.com\/. Accessed 24 May 2021."},{"issue":"13","key":"1562_CR7","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1007\/s40265-019-01186-x","volume":"79","author":"ZT Al-Salama","year":"2019","unstructured":"Al-Salama ZT, Frampton JE. Glycopyrronium\/formoterol: a review in COPD. Drugs. 2019;79(13):1455\u201366.","journal-title":"Drugs"},{"issue":"3","key":"1562_CR8","doi-asserted-by":"publisher","first-page":"395","DOI":"10.2165\/11208460-000000000-00000","volume":"72","author":"LJ Scott","year":"2012","unstructured":"Scott LJ. Budesonide\/formoterol Turbuhaler\u00ae: a review of its use in chronic obstructive pulmonary disease. Drugs. 2012;72(3):395\u2013414.","journal-title":"Drugs"},{"key":"1562_CR9","doi-asserted-by":"publisher","first-page":"101873","DOI":"10.1016\/j.pupt.2019.101873","volume":"60","author":"LJ Dunn","year":"2020","unstructured":"Dunn LJ, Kerwin EM, DeAngelis K, et al. Pharmacokinetics of budesonide\/glycopyrrolate\/formoterol fumarate metered dose inhaler formulated using co-suspension delivery technology after single and chronic dosing in patients with COPD. Pulm Pharmacol Ther. 2020;60:101873.","journal-title":"Pulm Pharmacol Ther"},{"issue":"105472","key":"1562_CR10","first-page":"1","volume":"153","author":"S Israel","year":"2020","unstructured":"Israel S, Kumar A, DeAngelis K, et al. Pulmonary deposition of budesonide\/glycopyrronium\/formoterol fumarate dihydrate metered dose inhaler formulated using co-suspension delivery technology in healthy male subjects. Eur J Pharm Sci. 2020;153(105472):1\u20139.","journal-title":"Eur J Pharm Sci"},{"issue":"4 Suppl","key":"1562_CR11","doi-asserted-by":"publisher","first-page":"A2435","DOI":"10.1016\/j.chest.2020.09.023","volume":"158","author":"O Usmani","year":"2020","unstructured":"Usmani O, Roche N, Abd Wahab E, et al. A scintigraphy study of budesonide\/glycopyrrolate\/formoterol fumarate in patients with COPD [abstract]. Chest. 2020;158(4 Suppl):A2435\u20137.","journal-title":"Chest"},{"key":"1562_CR12","unstructured":"Sheth P, Archbell J, Miller K, et al. Drug delivery from a novel fixed-dose ICS\/LAMA\/LABA MDI using co-suspension delivery technology: evidence of consistency, robustness, and reliability [poster presentation]. In: American Association of Pharmaceutical Scientists Pharmsci 360. 2019. https:\/\/www.eventscribe.com\/2019\/PharmSci360\/fsPopup.asp?Mode=posterinfo&PosterID=240490."},{"issue":"4 Suppl","key":"1562_CR13","doi-asserted-by":"publisher","first-page":"A1782","DOI":"10.1016\/j.chest.2020.08.1555","volume":"158","author":"M van den Berge","year":"2020","unstructured":"van den Berge M, De Backer J, Van Holsbeke C, et al. Functional respiratory imaging assessment of budesonide\/glycopyrrolate\/formoterol fumarate and glycopyrrolate\/formoterol fumarate metered dose inhalers in patients with COPD [abstract]. Chest. 2020;158(4 Suppl):A1782\u20133.","journal-title":"Chest"},{"key":"1562_CR14","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.pupt.2018.03.001","volume":"50","author":"P Darken","year":"2018","unstructured":"Darken P, DePetrillo P, Reisner C, et al. The pharmacokinetics of three doses of budesonide\/glycopyrronium\/formoterol fumarate dihydrate metered dose inhaler compared with active controls: a phase I randomized, single-dose, crossover study in healthy adults. Pulm Pharmacol Ther. 2018;50:11\u20138.","journal-title":"Pulm Pharmacol Ther"},{"key":"1562_CR15","doi-asserted-by":"publisher","first-page":"101976","DOI":"10.1016\/j.pupt.2020.101976","volume":"64","author":"Y Huang","year":"2020","unstructured":"Huang Y, Assam PN, Feng C, et al. Ethnic pharmacokinetic comparison of budesonide\/glycopyrrolate\/formoterol fumarate metered dose inhaler (BGF MDI) between Asian and Western healthy subjects. Pulm Pharmacol Ther. 2020;64:101976.","journal-title":"Pulm Pharmacol Ther"},{"issue":"5","key":"1562_CR16","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1016\/j.clinthera.2019.03.007","volume":"41","author":"Q Chen","year":"2019","unstructured":"Chen Q, Hu C, Yu H, et al. Pharmacokinetics and tolerability of budesonide\/glycopyrronium\/formoterol fumarate dihydrate and glycopyrronium\/formoterol fumarate dihydrate metered dose inhalers in healthy Chinese adults: a randomized, double-blind, parallel-group study. Clin Ther. 2019;41(5):897-909.e1.","journal-title":"Clin Ther"},{"issue":"1","key":"1562_CR17","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1056\/NEJMoa1916046","volume":"383","author":"KF Rabe","year":"2020","unstructured":"Rabe KF, Martinez FJ, Ferguson GT, et al. Triple inhaled therapy at two glucocorticoid doses in moderate-to-very-severe COPD. N Engl J Med. 2020;383(1):35\u201348.","journal-title":"N Engl J Med"},{"issue":"10","key":"1562_CR18","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1016\/S2213-2600(18)30327-8","volume":"6","author":"GT Ferguson","year":"2018","unstructured":"Ferguson GT, Rabe KF, Martinez FJ, et al. Triple therapy with budesonide\/glycopyrrolate\/formoterol fumarate with co-suspension delivery technology versus dual therapies in chronic obstructive pulmonary disease (KRONOS): a double-blind, parallel-group, multicentre, phase 3 randomised controlled trial. Lancet Respir Med. 2018;6(10):747\u201358.","journal-title":"Lancet Respir Med"},{"key":"1562_CR19","doi-asserted-by":"publisher","first-page":"2993","DOI":"10.2147\/COPD.S220861","volume":"14","author":"M Ichinose","year":"2019","unstructured":"Ichinose M, Fukushima Y, Inoue Y, et al. Long-term safety and efficacy of budesonide\/glycopyrrolate\/formoterol fumarate metered dose inhaler formulated using co-suspension delivery technology in Japanese patients with COPD. Int J Chron Obstruct Pulmon Dis. 2019;14:2993\u20133002.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"issue":"167","key":"1562_CR20","first-page":"1","volume":"20","author":"EM Kerwin","year":"2019","unstructured":"Kerwin EM, Ferguson GT, Mo M, et al. Bone and ocular safety of budesonide\/glycopyrrolate\/formoterol fumarate metered dose inhaler in COPD: a 52-week randomized study. Respir Res. 2019;20(167):1\u201314.","journal-title":"Respir Res"},{"key":"1562_CR21","first-page":"A2493","volume":"201","author":"KF Rabe","year":"2020","unstructured":"Rabe KF, Martinez FJ, Ferguson GT, et al. Single-inhaler triple combination therapy with budesonide\/glycopyrrolate\/formoterol fumarate metered dose inhaler (BGF MDI) at two corticosteroid dose levels in COPD: ETHOS trial [abstract]. Am J Respir Crit Care Med. 2020;201:A2493.","journal-title":"Am J Respir Crit Care Med"},{"issue":"Suppl 64","key":"1562_CR22","first-page":"977","volume":"56","author":"FJ Martinez","year":"2020","unstructured":"Martinez FJ, Rabe KF, Ferguson GT, et al. COPD exacerbation rates by month in the ETHOS trial with budesonide\/glycopyrronium\/formoterol metered dose inhaler (BGF MDI) at two ICS dose levels [abstract]. Eur Respir J. 2020;56(Suppl 64):977.","journal-title":"Eur Respir J"},{"issue":"Suppl 63","key":"1562_CR23","first-page":"PA2481","volume":"54","author":"KF Rabe","year":"2019","unstructured":"Rabe KF, Fabbri LM, Martinez FJ, et al. Analysis of exacerbation rates by time interval post-randomization in the KRONOS phase III study of budesonide\/glycopyrronium\/formoterol fumarate dihydrate metered dose inhaler (BGF MDI) [abstract]. Eur Respir J. 2019;54(Suppl 63):PA2481.","journal-title":"Eur Respir J"},{"key":"1562_CR24","unstructured":"European Medicines Agency. TRIXEO AEROSPHERE\u2122: assessment report. 2020. https:\/\/www.ema.europa.eu\/. Accessed 15 Jun 2021."},{"key":"1562_CR25","doi-asserted-by":"publisher","first-page":"2979","DOI":"10.2147\/COPD.S220850","volume":"14","author":"M Ichinose","year":"2019","unstructured":"Ichinose M, Fukushima Y, Inoue Y, et al. Efficacy and safety of budesonide\/glycopyrrolate\/formoterol fumarate metered dose inhaler formulated using co-suspension delivery technology in Japanese patients with COPD: a subgroup analysis of the KRONOS study. Int J Chron Obstruct Pulmon Dis. 2019;14:2979\u201391.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"issue":"4","key":"1562_CR26","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1007\/s12325-020-01266-5","volume":"37","author":"C Wang","year":"2020","unstructured":"Wang C, Yang T, Kang J, et al. Efficacy and safety of budesonide\/glycopyrrolate\/formoterol fumarate metered dose inhaler in Chinese patients with COPD: a subgroup analysis of KRONOS. Adv Ther. 2020;37(4):1591\u2013607.","journal-title":"Adv Ther"},{"key":"1562_CR27","first-page":"A16","volume":"76","author":"GT Ferguson","year":"2021","unstructured":"Ferguson GT, Rabe KF, Martinez FJ, et al. Rate of severe COPD exacerbations with budesonide\/glycopyrronium\/formoterol fumarate dihydrate metered dose inhaler (BGF MDI) versus dual therapies: a post-hoc subgroup analysis of the ETHOS trial [abstract]. Thorax. 2021;76:A16.","journal-title":"Thorax"},{"key":"1562_CR28","doi-asserted-by":"publisher","first-page":"179","DOI":"10.2147\/COPD.S286087","volume":"16","author":"FJ Martinez","year":"2021","unstructured":"Martinez FJ, Ferguson GT, Bourne E, et al. Budesonide\/glycopyrrolate\/formoterol fumarate metered dose inhaler improves exacerbation outcomes in patients with COPD without a recent exacerbation history: a subgroup analysis of KRONOS. Int J Chron Obstruct Pulmon Dis. 2021;16:179\u201389.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"1562_CR29","first-page":"A2246","volume":"203","author":"JR Hurst","year":"2021","unstructured":"Hurst JR, Martinez F, Singh D, et al. Benefits of budesonide\/glycopyrrolate\/formoterol fumarate metered dose inhaler in patients with chronic obstructive pulmonary disease by baseline CAT score: post-hoc analysis of the ETHOS study [abstract]. Am J Respir Crit Care Med. 2021;203:A2246.","journal-title":"Am J Respir Crit Care Med"},{"key":"1562_CR30","doi-asserted-by":"publisher","first-page":"A2245","DOI":"10.1164\/rccm.202101-0145ED","volume":"203","author":"D Singh","year":"2021","unstructured":"Singh D, Rabe K, Martinez F, et al. Relationship between prior inhaled corticosteroid use and benefits of budesonide\/glycopyrrolate\/formoterol fumarate on exacerbation risk in patients with chronic obstructive pulmonary disease: analysis from the ETHOS study [abstract]. Am J Respir Crit Care Med. 2021;203:A2245.","journal-title":"Am J Respir Crit Care Med"},{"key":"1562_CR31","first-page":"A1244","volume":"203","author":"MK Han","year":"2021","unstructured":"Han MK, Jenkins M, Carstens D, et al. Safety and efficacy of budesonide-glycopyrrolate-formoterol fumarate for COPD in Black or African-American patients: a post-hoc subgroup analysis of the ETHOS study [abstract]. Am J Respir Crit Care Med. 2021;203:A1244.","journal-title":"Am J Respir Crit Care Med"},{"key":"1562_CR32","first-page":"A2244","volume":"203","author":"G Ferguson","year":"2021","unstructured":"Ferguson G, Rabe K, Singh D, et al. Benefits of budesonide\/glycopyrrolate\/formoterol fumarate metered dose inhaler in patients with moderate chronic obstructive pulmonary disease in the ETHOS study [abstract]. Am J Respir Crit Care Med. 2021;203:A2244.","journal-title":"Am J Respir Crit Care Med"},{"key":"1562_CR33","first-page":"A5074","volume":"201","author":"KF Rabe","year":"2020","unstructured":"Rabe KF, Martinez FJ, Singh D, et al. Improvements in lung function with budesonide\/glycopyrrolate\/formoterol fumarate metered dose inhaler (BGF MDI) versus dual therapies in patients with COPD: a sub-study of the ETHOS trial [abstract no. P1069 and poster]. Am J Respir Crit Care Med. 2020;201:A5074.","journal-title":"Am J Respir Crit Care Med"},{"key":"1562_CR34","first-page":"A3351","volume":"199","author":"GT Ferguson","year":"2019","unstructured":"Ferguson GT, Rabe KF, Bourne E, et al. 12-hour lung function assessment of budesonide\/glycopyrrolate\/formoterol fumarate metered dose inhaler (BGF MDI) delivered by co-suspension delivery technology in patients with COPD [abstract no. B45]. Am J Respir Crit Care Med. 2019;199:A3351.","journal-title":"Am J Respir Crit Care Med"},{"key":"1562_CR35","first-page":"A5073","volume":"201","author":"FJ Martinez","year":"2020","unstructured":"Martinez FJ, Rabe KF, Ferguson GT, et al. Benefits of budesonide\/glycopyrrolate\/formoterol fumarate metered dose inhaler (BGF MDI) on symptoms and quality of life in patients with chronic obstructive pulmonary disease (COPD) in the ETHOS trial [abstract no. P1068 and poster]. Am J Respir Crit Care Med. 2020;201:A5073.","journal-title":"Am J Respir Crit Care Med"},{"issue":"5","key":"1562_CR36","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1164\/rccm.202006-2618OC","volume":"203","author":"F Martinez","year":"2020","unstructured":"Martinez F, Rabe K, Ferguson G, et al. Reduced all-cause mortality in the ETHOS trial of budesonide\/glycopyrrolate\/formoterol for chronic obstructive pulmonary disease. A randomized, double-blind, multicenter, parallel-group study. Am J Respir Crit Care Med. 2020;203(5):553\u201364.","journal-title":"Am J Respir Crit Care Med"},{"key":"1562_CR37","first-page":"A6298","volume":"201","author":"GT Ferguson","year":"2020","unstructured":"Ferguson GT, Rabe KF, Martinez FJ, et al. Cardiovascular safety of budesonide\/glycopyrrolate\/formoterol fumarate metered dose inhaler formulated using co-suspension delivery technology in chronic obstructive pulmonary disease (COPD): a 24-hour holter monitoring sub-study of the ETHOS trial [abstract no. 718 and poster]. Am J Respir Crit Care Med. 2020;201:A6298.","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"1562_CR38","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1080\/17476348.2020.1816830","volume":"15","author":"L Calzetta","year":"2020","unstructured":"Calzetta L, Ritondo BL, de Marco P, et al. Evaluating triple ICS\/LABA\/LAMA therapies for COPD patients: a network meta-analysis of ETHOS, KRONOS, IMPACT, and TRILOGY studies. Expert Rev Respir Med. 2020;15(1):143\u201352.","journal-title":"Expert Rev Respir Med"},{"issue":"4","key":"1562_CR39","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1016\/j.chest.2018.12.016","volume":"155","author":"L Calzetta","year":"2019","unstructured":"Calzetta L, Cazzola M, Matera MG, et al. Adding a LAMA to ICS\/LABA therapy: a meta-analysis of triple combination therapy in COPD. Chest. 2019;155(4):758\u201370.","journal-title":"Chest"},{"issue":"4","key":"1562_CR40","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1159\/000470818","volume":"41","author":"Y Zhu","year":"2017","unstructured":"Zhu Y, Zhang T, Li H, et al. Discovering the relative efficacy of inhaled medications for chronic obstructive pulmonary disease: multiple treatment comparisons. Cell Physiol Biochem. 2017;41(4):1532\u201346.","journal-title":"Cell Physiol Biochem"},{"issue":"6","key":"1562_CR41","doi-asserted-by":"publisher","first-page":"2956","DOI":"10.1007\/s12325-020-01311-3","volume":"37","author":"GT Ferguson","year":"2020","unstructured":"Ferguson GT, Darken P, Ballal S, et al. Efficacy of budesonide\/glycopyrronium\/formoterol fumarate metered dose inhaler (BGF MDI) versus other inhaled corticosteroid\/long-acting muscarinic antagonist\/long-acting \u03b2(2)-agonist (ICS\/LAMA\/LABA) triple combinations in COPD: a systematic literature review and network meta-analysis. Adv Ther. 2020;37(6):2956\u201375.","journal-title":"Adv Ther"},{"key":"1562_CR42","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-021-01703-z","author":"A Bourdin","year":"2021","unstructured":"Bourdin A, Molinari N, Ferguson GT, et al. Efficacy and safety of budesonide\/glycopyrronium\/formoterol fumarate versus other triple combinations in COPD: a systematic literature review and network meta-analysis. Adv Ther. 2021. https:\/\/doi.org\/10.1007\/s12325-021-01703-z.","journal-title":"Adv Ther"},{"key":"1562_CR43","first-page":"A2249","volume":"203","author":"E De Nigris","year":"2021","unstructured":"De Nigris E, Treharne C, Brighton N, et al. Projections of healthcare resource utilization and costs related to exacerbations for budesonide\/glycopyrrolate\/formoterol fumarate versus dual long-acting muscarinic antagonist\/long-acting \u03b22-agonist and inhaled corticosteroid\/long-acting \u03b22-agonist therapies in moderate-to-very severe chronic obstructive pulmonary disease [abstract]. Am J Respir Crit Care Med. 2021;203:A2249.","journal-title":"Am J Respir Crit Care Med"},{"key":"1562_CR44","first-page":"A2248","volume":"203","author":"E de Nigris","year":"2021","unstructured":"de Nigris E, Treharne C, Brighton N, et al. Lifetime benefits for budesonide\/glycopyrrolate\/formoterol fumarate versus long-acting muscarinic antagonist\/long-acting \u03b22-agonist and inhaled corticosteroid\/long-acting \u03b22-agonist therapies in moderate-to-very severe chronic obstructive pulmonary disease [abstract]. Am J Respir Crit Care Med. 2021;203:A2248.","journal-title":"Am J Respir Crit Care Med"},{"issue":"Suppl 63","key":"1562_CR45","first-page":"PA2484","volume":"54","author":"M Polyzoi","year":"2019","unstructured":"Polyzoi M, Treharne C, McCrea C, et al. Estimated lifetime effectiveness of triple therapy with budesonide\/glycopyrrolate\/formoterol fumarate metered dose inhaler (BGF MDI) versus dual LAMA\/LABA and ICS\/LABA therapies in moderate-to-very severe COPD [abstract]. Eur Respir J. 2019;54(Suppl 63):PA2484.","journal-title":"Eur Respir J"}],"updated-by":[{"DOI":"10.1007\/s40265-021-01595-x","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2021,8,28]],"date-time":"2021-08-28T00:00:00Z","timestamp":1630108800000}}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-021-01562-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-021-01562-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-021-01562-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,30]],"date-time":"2021-09-30T13:31:38Z","timestamp":1633008698000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-021-01562-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8]]},"references-count":45,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["1562"],"URL":"https:\/\/doi.org\/10.1007\/s40265-021-01562-6","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8]]},"assertion":[{"value":"22 June 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 August 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 August 2021","order":3,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":4,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":5,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s40265-021-01595-x","URL":"https:\/\/doi.org\/10.1007\/s40265-021-01595-x","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The preparation of this review was not supported by any external funding.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Young-A Heo is a salaried employee of Adis International Ltd\/Springer Nature, and declares no relevant conflicts of interest. All authors contributed to the review and are responsible for the article content.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authorship and Conflict of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval, Consent to participate, Consent to publish, Availability of data and material, Code availability"}}]}}